Coronavirus (COVID-19) Collection
SARS-CoV-2 vertical transmission in a twin-pregnant woman: a case report
SARS-CoV-2 represents one of the most threatening infections in the last century, affecting millions of people worldwide (World Health Organization, 2020) ( covid19.who.int ).Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study
The rapid spread of an enveloped RNA betacoronavirus (2019) (Lu et al., 2020), SARS-CoV-2 (Guan et al., 2020), causing COVID-19, led to a global pandemic (declared by the World Health Organization [WHO] on March 11, 2020) (World Health Organization [WHO], 2020a), with more than 266 million cases and 5 million deaths worldwide (WHO, 2021).Characteristics and outcomes of vaccinated and nonvaccinated patients hospitalized in a single Italian hub for COVID-19 during the Delta and Omicron waves in Northern Italy
Since the emergence of SARS-CoV-2 pandemic that causes COVID-19, several efforts have been made to contain and prevent the spread of infection and disease. Among the available interventions, population-based vaccination campaigns have been implemented worldwide after the development of highly effective vaccines (Baden et al., 2021; Polack et al., 2020; Sadoff et al., 2021; Voysey et al., 2021). In Italy, the vaccination campaign started on December 27, 2020, and the following vaccines were adopted for immunization: BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), ChAdOx1 (AstraZeneca), and Ad26.COV2.S (Janssen).Measuring the impact of a single dose of ChAdOx1 nCoV-19 (recombinant) coronavirus vaccine on hospital stay, ICU requirement, and mortality outcome in a tertiary care centre
On March 11, 2020, WHO declared COVID-19 to be a pandemic [World Health Organization, 2020]. Most of countries have since faced significant challenges in combating this disease. By June 2021, the cumulative number of cases reported globally had exceeded 180 million, and the number of global deaths had reached almost 4 million across 216 countries.Neutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patients
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease 19 (COVID-19), emerged in late 2019 and rapidly spread worldwide, causing a global pandemic (Lipsitch et al., 2020). Despite many insights on the virus, data regarding the long-term immune response are quite scarce (Huang et al., 2020), although this issue is of high clinical relevance.Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study
Natural SARS-CoV-2 infection elicits humoral (Percivalle et al., 2020; Ni et al., 2020; Muecksch et al., 2021) and cellular responses (Grifoni et al., 2020). However, little is known about protection against secondary infection. Recently, a longitudinal study conducted in the United Kingdom (Lumley et al., 2021) showed that SARS-CoV-2 seropositivity was associated with a lower SARS-CoV-2 RNA detection rate.Multisystem inflammatory syndrome in adults: A rare sequela of SARS-CoV-2 infection
Most of our understanding of MIS-A is based on various case reports and case series shared by the CDC and published in the medical literature (Bastug et al., 2021; Morris et al., 2020). Here we describe a case of MIS-A in a patient admitted to the Creighton University Medical Center —Bergan Mercy campus in Omaha, Nebraska with clinical presentation and diagnostics suggestive of MIS-A.Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach
Patients with pre-existing comorbidities and immunosuppression, including anti-CD20 monoclonal antibody, widely used to treat hematological malignancies or autoimmune disease, are at greater risk for persistent Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2) infection (He et al., 2020). Prolonged B-cell depletion impairs the adaptive immune response and the ability to produce neutralizing antibodies, causing severe manifestations and a prolonged course of COVID-19 (Mehta et al., 2020; Hueso et al., 2020).Cutaneous manifestations associated with anosmia, ageusia and enteritis in SARS-CoV-2 infection – A possible pattern? Observational study and review of the literature
The cutaneous manifestations of coronavirus disease 2019 (COVID-19) have been covered insufficiently in the literature.Is it all MIS-C? Unusual findings in a series of nine German patients with multi-system inflammatory syndrome in children after SARS-CoV-2 infection
Multi-system inflammatory syndrome in children (MIS-C) is a post-viral inflammatory vasculopathy of children and adolescents following coronavirus disease 2019 (COVID-19). Since its first description in May 2020 (Verdoni et al., 2020), specific diagnostic criteria have been issued by the Centers for Disease Control and Prevention (2020) and the World Health Organization (2020). Recently, case series have been reported from the UK (Davies et al., 2020) and Spain (Garcia-Salido et al., 2020), and a systematic review has summarized numerous cases of MIS-C from European, American and Asian countries (Radia et al., 2020).Impact of low serum calcium at hospital admission on SARS-CoV-2 infection outcome
Severe Acute Respiratory Syndrome Coronavirus 2, named SARS-CoV-2, was isolated in January 2020 after an outbreak of respiratory infections originated in December 2019 in the city of Wuhan, China (Zhu et al., 2020). The virus spread rapidly, first to neighboring countries and weeks afterward throughout the world, causing a worldwide pandemic.Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: A retrospective study from Burkina Faso and simulated case analysis
At 6 months after SARS-CoV-2 (COVID-19) was introduced into the region, countries across sub-Saharan Africa (SSA) were reporting significantly fewer cases than higher income countries and some low-middle-income countries (LMICs) on other continents (World Health Organization, 2020b). As a result, the majority of evidence to date reflects disease progression, hospitalization rates and deaths among cases in more developed and higher transmission settings across Europe, North America (CDC COVID-19 Response Team, 2020) and Asia (Chen et al., 2020; Guan et al., 2020).Unheralded Lower limb threatening ischemia in a COVID-19 patient
A 58-year-old man was urgently transferred to our COVID-19 intensive care unit from the intensive care unit of a dedicated COVID-19 hospital, due to the sudden onset of ischemia of the right forefoot.
